Vessimed
Nesher, IL · 9 employees on LinkedIn · 2 known investors
Vessi Medical develops a minimally invasive cryo spray system for treating urological conditions in the bladder, offering a non-surgical alternative to traditional procedures performed in hospital settings. The system enables office-based treatment without anesthesia in some cases, reducing complications and healthcare costs compared to conventional surgical approaches.
Also known as Vessi · Vessi Medical
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Vessi Medical is an Israeli medical device company developing a patent-protected cryo spray system for ablation of tissue in hollow and humid organs, with an initial focus on urological tissue in the bladder. The company applies surface cryotherapy — the use of extreme cold to freeze and destroy abnormal tissue — as an ablative approach to non-muscle invasive bladder cancer (NMIBC).
The Vessi system consists of a standalone console and a disposable device or catheter that is inserted transurethrally into the bladder, in a manner similar to existing intravesical techniques. The company describes the approach as non-contact ablation with visualization inside hollow organs and in mixed liquid and gas environments during treatment, and with cooling temperature and pressure balanced for the application. Vessi positions the system as an office-based procedure that in some cases can be performed without anesthesia.
Business model
Development-stage medical device company building a capital-equipment console paired with a single-use disposable device intended for use by urologists.
Traction
A first-in-human procedure was completed in July 2021 at Rambam Healthcare Campus. The company reported ease of use, speed of activation and completion, no complications or bleeding, clear inner bladder visualization and tumor reaction, with the patient discharged the following day reporting no pain.
Latest developments
The company's website states that first-in-human clinical trials were initiated in 2021 and describes the Vessi system of console plus disposable transurethral device.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Vessi Medical positions its system as an alternative to transurethral resection of bladder tumor (TURBT), the current first-line treatment for non-muscle invasive bladder cancer, which the company characterizes as a costly and invasive surgical procedure performed under general anesthesia with recurrence of cancer in up to 60% of cases and frequent complications.
The company describes its cryo spray as purpose-built for hollow and humid organs, with bladder-specific surface cryotherapy delivered without tissue contact, visualization within mixed liquid and gas environments, and a design intended for office use rather than a hospital operating room under general anesthesia. In the first-in-human case, physicians reported that the procedure worked like a simple cystoscopy, implying a short learning curve, with no bleeding and good visibility.
Technology
Surface cryotherapy delivered as a cryo spray through a disposable, transurethrally inserted device connected to a standalone console. Treatment in the first-in-human case involved two cycles of freezing and thawing intended to produce apoptosis and necrosis of the lesion, with the lesion reported to freeze completely within seconds and thaw quickly.
Go-to-market
Patients with non-muscle invasive (superficial) bladder cancer and the urologists and healthcare facilities treating them; the CEO has also cited potential future application to other bladder diseases such as overactive bladder.
Geography
Headquartered at 47 HaTa'asiya Street, Nesher, Israel; a 2021 press release listed Misgav, Israel as the company's location, and the first-in-human procedure was conducted at Rambam Healthcare Campus in Haifa, Israel.
History
Vessi Medical was founded in 2017 according to The Trendlines Group's portfolio listing. First-in-human clinical trials were initiated in 2021, with the first case performed at Rambam Healthcare Campus in Haifa, Israel, in a study intended to support product development toward the regulatory process.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsVessi Medical completed a first-in-human case with its minimally invasive cryoablation solution for superficial bladder cancer (NMIBC) at Rambam Healthcare Campus in Haifa, Israel. The procedure was reported without complications or bleeding, with clear inner bladder visualization and good tumor reaction; the patient was discharged the following day. The case marked the start of the company's first-in-human study supporting product development toward regulatory approval.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Vessimedvessimed.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vessimed do?
- Israeli medical device company developing a cryo spray ablation system for non-muscle invasive bladder cancer.
- Who founded Vessimed?
- Vessimed was founded by Eyal Kochavi.
- Who are Vessimed's investors?
- Vessimed's investors include ALIVE Israel HealthTech Fund, Trendlines Group.
- Where is Vessimed headquartered?
- Vessimed is headquartered in Nesher, IL.